QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
NASDAQ:ABUS

Arbutus Biopharma - ABUS Earnings Date, Estimates & Call Transcripts

$1.97
+0.03 (+1.55%)
(As of 10/4/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.92
$1.97
50-Day Range
$1.88
$2.54
52-Week Range
$1.85
$6.50
Volume
657,843 shs
Average Volume
1.50 million shs
Market Capitalization
$295.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.13

Earnings Summary

Upcoming
Earnings Date
Nov. 3Estimated
Actual EPS
(Aug. 4)
-$0.10 Beat By $0.03
Consensus EPS
(Aug. 4)
-$0.13
Last Year's Q3 EPS
(8/4/2021)
-$0.23
Skip Charts & View Estimated and Actual Earnings Data

ABUS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ABUS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Arbutus Biopharma Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20222($0.15)($0.14)($0.15)
Q2 20222($0.15)($0.14)($0.15)
Q3 20222($0.15)($0.14)($0.15)
Q4 20222($0.14)($0.13)($0.14)
FY 20228($0.59)($0.55)($0.57)
Q1 20231($0.13)($0.13)($0.13)
Q2 20231($0.14)($0.14)($0.14)
Q3 20231($0.14)($0.14)($0.14)
Q4 20231($0.15)($0.15)($0.15)
FY 20234($0.56)($0.56)($0.56)

ABUS Earnings Date and Information

Arbutus Biopharma last announced its quarterly earnings data on August 4th, 2022. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. The business earned $14.24 million during the quarter, compared to the consensus estimate of $5.37 million. Arbutus Biopharma has generated ($0.60) earnings per share over the last year (($0.60) diluted earnings per share). Earnings for Arbutus Biopharma are expected to decrease in the coming year, from ($0.44) to ($0.64) per share. Arbutus Biopharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 3rd, 2022 based off prior year's report dates.

Arbutus Biopharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/3/2022
(Estimated)
        
8/4/2022Q2 2022($0.13)($0.10)+$0.03($0.10)$5.37 million$14.24 million    
5/5/2022Q1 2022($0.13)($0.11)+$0.02($0.11)$5.77 million$12.58 million    
3/3/2022Q4 2021($0.16)($0.15)+$0.01($0.15)$3.39 million$3.21 million    
11/4/20219/30/2021($0.24)($0.24)($0.24)$2.36 million$3.34 million    
8/4/20216/30/2021($0.21)($0.23)($0.02)($0.23)$2.07 million$2.33 million    
5/4/20213/31/2021($0.23)($0.21)+$0.02($0.21)$3.87 million$2.11 million  
3/3/202112/31/2020($0.22)($0.23)($0.01)($0.23)$2.12 million$2.39 million    
11/10/20209/30/2020($0.22)($0.27)($0.05)($0.27)$1.81 million$1.52 million    
8/7/20206/30/2020($0.24)($0.25)($0.01)($0.25)$1.85 million$1.51 million  
5/11/20203/31/2020($0.31)($0.25)+$0.06($0.25)$1.81 million$1.49 million  
3/5/2020Q4 2019($0.37)($0.36)+$0.01($0.26)$1.46 million$1.61 million
11/6/2019Q3 2019($0.11)($0.33)($0.22)$0.84$9.85 million$3.10 million  
8/5/2019Q2($0.35)($0.46)($0.11)($0.46)$0.88 million$0.70 million  
5/6/20193/31/2019($0.31)($0.47)($0.16)($0.47)$1.18 million$0.70 million    
3/7/201912/31/2018($0.39)($0.37)+$0.02($0.37)$0.77 million$1.60 million    
11/7/20189/30/2018($0.39)($0.52)($0.13)($0.11)$0.23 million$1.59 million
8/2/20186/30/2018($0.35)($0.44)($0.09)($0.89)$1.20 million
5/3/20183/31/2018($0.39)($0.36)+$0.03($0.36)$1.40 million
3/14/2018After Market($0.39)($0.90)($0.51)($1.13)$0.70 million$2.50 million  
11/2/2017Q3 2017($0.38)($0.17)+$0.21($0.13)$0.79 million$6.90 million
8/3/2017Q2 2017($0.35)($0.28)+$0.07($0.23)$0.68 million$1.00 million
5/4/20173/31/2017($0.30)($0.34)($0.04)($0.34)$7.50 million$0.20 million  
3/21/2017Q4 2016($0.38)($0.38)$3.33$0.76 million($0.20) million
11/3/2016Q3 2016($0.53)($0.31)+$0.22($0.25)$0.44 million$0.70 million
8/4/2016Q2 2016($0.35)($0.35)$1.77$0.99 million$0.30 million
5/4/2016Q1 2016($0.37)($0.31)+$0.06($0.31)$1.25 million$0.60 million
3/9/2016Q4 2015($0.39)$0.31+$0.70$0.68$2.55 million$12.71 million
11/5/2015Q3 2015($0.31)($0.42)($0.11)($0.27)$3.37 million$4.10 million
8/5/2015Q2($0.25)($0.20)+$0.05($0.13)$3.77 million$3.40 million
5/6/2015Q1 2015($0.39)($0.40)($0.01)($0.40)$3.55 million$4.70 million
3/12/2015Q4 2014($0.32)($0.27)+$0.05($0.27)$6.12 million$4.40 million
11/6/2014Q314($0.40)($0.39)+$0.01($0.39)$3.71 million$4.40 million  
8/14/2014Q214($0.13)($0.11)+$0.02$0.06$3.72 million$1.80 million
5/14/2014Q1 2014$0.40($0.22)($0.62)$0.47$18.55 million$4.43 million
3/6/2014Q4 2013($0.02)($0.07)($0.05)$0.01$7.57 million$7.60 million
12/18/2013Q3($0.07)($0.12)($0.05)  
11/13/2013Q3 2013($0.03)($0.24)($0.21)($0.08)$7.50 million$2.91 million
8/12/2013Q2 2013($0.24)($0.21)+$0.03($0.21)$2.50 million$2.82 million
5/14/2013Q1 2013($0.14)($0.18)($0.04)($0.18)$3.00 million$2.16 million
3/27/2013Q4 2012($0.07)($0.38)($0.31)($3.23)
12/18/2012Q3 2012($0.07)($0.12)($0.05)$0.01
8/14/2012Q2 2012($0.16)($0.19)($0.03)($0.24)
5/15/2012Q1 2012($0.17)($0.25)($0.08)($0.25)
3/27/2012Q4 2011$0.20($0.16)($0.36)($0.17)
11/8/2011Q3 2011($0.30)($0.12)+$0.18($0.12)
8/11/2011Q2 2011($0.31)($0.35)($0.04)($0.36)
5/11/2011Q1 2011($0.36)($0.31)+$0.05($0.31)
3/17/2010Q4 2009($0.05)($0.05)($0.05)
3/24/2009Q4 2008($0.06)($0.06)($0.06)
11/13/2008Q3 2008($0.11)($0.11)($0.11)
8/14/2008Q2 2008($0.14)($0.14)($0.14)
5/14/2008Q1 2008($0.02)($0.02)($0.02)
3/31/2008Q4 2007$0.01+$0.01$0.01












Arbutus Biopharma Earnings - Frequently Asked Questions

When is Arbutus Biopharma's earnings date?

Arbutus Biopharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 3rd, 2022 based off last year's report dates. Learn more on ABUS's earnings history.

Did Arbutus Biopharma beat their earnings estimates last quarter?

In the previous quarter, Arbutus Biopharma (NASDAQ:ABUS) reported ($0.10) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.13) by $0.03. Learn more on analysts' earnings estimate vs. ABUS's actual earnings.

How can I listen to Arbutus Biopharma's earnings conference call?

The conference call for Arbutus Biopharma's latest earnings report can be listened to online. Listen to Conference Call

How can I read Arbutus Biopharma's conference call transcript?

The conference call transcript for Arbutus Biopharma's latest earnings report can be read online. Read Transcript

How much revenue does Arbutus Biopharma generate each year?

Arbutus Biopharma (NASDAQ:ABUS) has a recorded annual revenue of $10.99 million.

How much profit does Arbutus Biopharma generate each year?

Arbutus Biopharma (NASDAQ:ABUS) has a recorded net income of -$76.25 million. ABUS has generated -$0.60 earnings per share over the last four quarters.

What is Arbutus Biopharma's EPS forecast for next year?

Arbutus Biopharma's earnings are expected to decrease from ($0.44) per share to ($0.64) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:ABUS) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.